Home
|
Contact Us
|
661-775-5300
|
Knowledge Center
|
Overview
Diabetes: AFREZZA
®
Diabetes: MKC253
Cancer: MKC1106 Platform
Cancer: MKC204
Clinical Trials
Overview
Dry Powder
Delivery Platform
Inhalers
Inhalation Profiling
MannKind Technologies
Overview
Stock Information
Investors FAQs
SEC Filings
Analyst Coverage
Annual Reports
Quarterly Reports
Request Materials
Email Alerts
Press Releases
In the News
Events
Webcasts
Media Room
Photos
External Diabetes Resources
Overview
Our Values
Corporate Governance
Executive Management
Alfred E. Mann
Hakan S. Edstrom
Matthew J. Pfeffer
Juergen A. Martens
Diane M. Palumbo
David B. Thomson
Board of Directors
Alfred E. Mann
Ronald Consiglio
Hakan S. Edstrom
Michael Friedman, M.D.
Kent Kresa
David H. MacCallum
Henry L. Nordhoff
Committee Composition
Scientific Advisors
Awards
Locations
Contact Us
Register for Updates
Overview
Job Search
Update Your Profile
Create a Job Agent
Update Job Agent
Total Rewards
Press Releases
In the News
Events
Webcasts
Media Room
ShareThis
Print
Text Size
In The News
Recent articles featuring MannKind Corporation:
PharmaVOICE 100 (PharmaVoice, August 2010)
"Capturing lightning In A Bottle" (PharmPro, July 2010)
Inhaled Insulin Appears to be on the Rebound (Drug Topics, July 2010)
Advances in diabetes treatment (FOX Tampa, June 2010)
Inhaled Insulin Plus Basal Insulin Reduces Hypoglycaemic Episodes in Patients With Type 2 Diabetes: Presented at AACE(Doc Guide, April, 2010)
LABJ-MannKind Studies Show Afrezza Safe, Effective (LA Business Journal, April 2010)
